4552   JCR Pharmaceuticals Co.,Ltd.

03/27/2025 16:00	JCR Revises Full-Year Consolidated Forecast for FY2024
02/27/2025 16:00	Change in Duties of Corporate Officers, Organizational and Personnel Changes
02/25/2025 16:00	Notice Concerning the Start of Construction of a New Drug Product Plant
02/21/2025 13:00	JCR Pharmaceuticals Proudly Supports Rare Disease Day 2025
01/31/2025 16:00	Summary of Financial Results for the third quarter 2025
01/31/2025 16:00	Financial Summary Consolidated Financial Results for the Nine Months ended December 31, 2024 (FY2024) (Japanese standard)
01/31/2025 16:00	Revision of Consolidated Financial Forecasts for Fiscal Year Ended March 31, 2025
01/31/2025 16:00	FY2024 Third Quarter Consolidated Financial Results Conference Call
01/28/2025 21:30	JCR Pharmaceuticals to Present at the 21st Annual WORLDSymposiumTM 2025
01/06/2025 13:00	[Updated]JCR and Modalis Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy
01/06/2025 12:00	JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy
12/25/2024 14:00	JCR Pharmaceuticals Receives MHLW Orphan Drug Designation for JR-441 for the Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)
12/19/2024 16:00	JCR Pharmaceuticals Initiates Phase III Clinical Trial of JR-142 in Japan, a Long-Acting Growth Hormone Therapy
12/03/2024 16:00	MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Announce Initiation of First Dosing in Phase I/II Clinical Trial of JR-446 for MPS IIIB in Japan
11/21/2024 16:00	FY2024 R&Dmeeting Meterial
11/19/2024 13:00	JCR Sponsors Family Health Activities at ORGAN ROOMS PROJECT
11/18/2024 14:30	[Delayed]Financial Summary Consolidated Financial Results for the Six Months ended September 30, 2024 (FY2024) (Japanese standard)
11/01/2024 09:30	Notice Regarding the Result and Completion of Repurchase of Own Shares through Off-Auction Own Share Repurchase Trading System (ToSTNeT-3)
10/31/2024 16:00	Notice of Repurchase of Own Shares through the Off-Auction Own Share Repurchase Trading System (ToSTNeT-3)
10/31/2024 15:30	JCR Initiates First Dosing in Phase I Clinical Trial of JR-441 for Mucopolysaccharidosis Type IIIA
10/30/2024 16:30	Financial Summary Consolidated Financial Results for the Six Months ended September 30-2024_FY2024_Japanese standard_Flash Report
10/30/2024 16:30	FY2024 Second Quarter Results Briefing Session
10/30/2024 16:00	Summary of Financial Results for the second quarter 2025
10/30/2024 16:00	Notice of Repurchase of Own Shares through the Off-Auction Own Share Repurchase Trading System (ToSTNeT-3)
10/30/2024 16:00	Notice of Personnel Change
10/30/2024 16:00	Notice of Distribution of Retained Earnings (Interim Dividend)
10/23/2024 11:30	JCR Pharmaceuticals Presents Preclinical Gene Therapy Research at the European Society of Gene and Cell Therapy 31st Annual Congress
10/16/2024 16:00	JCR Pharmaceuticals to Present at the European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress
09/02/2024 16:00	[Delayed]JCR Continues Support for Relay For Life Japan and Relay For Life of ASHIYA
08/29/2024 16:00	JCR Pharmaceuticals Announces Completion of Clinical Trial Notification Process in Japan for Phase I Study of JR-441 for MPS IIIA
08/23/2024 16:45	[Delayed]Financial Summary Consolidated Financial Results for the Three Months ended June 30, 2024 (FY2024) (Japanese standard)
08/22/2024 17:00	Notice Regarding the Completion of Payment for the Disposition of Treasury Stock as Restricted Stock Compensation
07/30/2024 16:00	Summary of Financial Results for the first quarter 2025
07/30/2024 16:00	Financial Summary Consolidated Financial Results for the Three Months ended June 30, 2024 (FY2024) (Japanese standard) (Flash Report)
07/30/2024 16:00	FY2024 First Quarter Results Conference Call
07/30/2024 16:00	JCR Pharmaceuticals Announces Discontinuation of TEMCELL HS Inj. Expanded Indication Development for Neonatal Hypoxic Ischemic Encephalopathy
07/23/2024 16:00	Notice Regarding the Disposition of Treasury Stock as Restricted Stock Compensation
07/18/2024 16:00	JCR Pharmaceuticals Highlights Innovative Gene Therapy Research at the 7th International Forum of Lysosomal Disorders
07/05/2024 15:30	JCR Organizes API Plant Tour for Local Residents
07/03/2024 16:00	[Delayed]Notice of Personnel and Organizational Changes
07/01/2024 16:00	MEDIPAL and JCR Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIB
06/26/2024 16:00	Matters Concerning Controlling Shareholders (Affiliated Companies)
06/25/2024 18:30	JCR Pharmaceuticals Regains Full Commercialization Rights to JR-141
06/05/2024 08:00	Other Matters Subject to Measures for Electronic Provision When Convening the 49th Ordinary General Meeting of Shareholders
06/05/2024 08:00	Notice of Convocation of The 49th Ordinary General Meeting of Shareholders
05/31/2024 15:35	[Delayed]Financial Summary Consolidated Financial Results for the Year ended March 31, 2024 (FY2023) (Japanese standard)
05/24/2024 12:00	[Delayed]Appendix to the Consolidated Financial Summary FY2023 Second-Half (Full version)
05/13/2024 11:45	FY2023 Results Briefing Session -Material-
05/13/2024 11:30	[Updated] Appendix to the Consolidated Financial Summary FY2023 Second-Half (Flash report)
05/10/2024 17:00	Appendix to the Consolidated Financial Summary FY2023 Second-Half (Flash report)
05/10/2024 16:00	Notice Regarding Introduction of a Restricted Stock Compensation Plan and Revision to the Amount of Compensation for Directors
05/10/2024 16:00	Notice of Distribution of Retained Earnings
05/10/2024 16:00	Summary of Financial Results 2024
04/25/2024 16:00	Notice of Personnel Change
04/25/2024 16:00	Notice Regarding Nomination of a Candidate to the Board of Director
04/22/2024 14:00	JCR Pharmaceuticals Announces Naming Rights Partnership for "Uchibun"